Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?

Executive Summary

Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.

Related Content

Merck’s Vioxx Recall Features Extensive Publicity Campaign To 2 Mil.
FDA “Case Studies” On Dosing Problems Include Lotronex, Crestor
FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit
AstraZeneca Agrees To Limit Distribution, Promotion Of Crestor 40 Mg
Bayer’s Baycol Settlements Coming At Quicker Pace; 785 Suits Settled So Far
AstraZeneca Launches Crestor In Canada At 15% Discount To Lipitor
AstraZeneca Crestor NDA Includes Rhabdomyolysis Reports At Highest Dose
Novartis Zomaril NDA Filing Awaits More Data On QTc Prolongation
Sanofi Modifying Plavix Adverse Event Reporting Procedures After FDA Letter
Bayer Pharma Sale Remains Long-Term Option; CFO Wenning To Become CEO



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts